Amylyx (AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/Amylyx+%28AMLX%29+Falls+70%25+After+Phase+3+PHOENIX+Trial+of+AMX0035+in+ALS+Did+Not+Meet+Prespecified+Primary+or+Secondary+Endpoints/22904534.html for the full story.